

CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY

2023

ANNUAL REPORT



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Connect with Us

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

 WeChat.com/IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER



Table of Contents

04

Welcome Letter

05

Membership

08

IASLC Strategic Plan

10

Scientific Affairs

19

Conferences and Events

25

Educations

28

Webinars

32

JTO & JTO CRR

35

IASLC Lung Cancer News

37

Podcasts

39

Committees

44

Patient Advocacy

46

DEI

47

IASLC Partners

48

Corporate Relations

49

IASLC Foundation, LLC

53

IASLC Board of Directors

54

IASLC Staff



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Welcome

Dear Colleagues and Friends,

2023 was a year of growth for IASLC. We crossed a historic milestone as our membership surpassed the **10,000** mark, and more than **7,800** delegates met both in person and online at our various events this year.

Our membership growth has led us to expand our committee structure, allowing us to put more resources into focusing on topics vital to our membership and their mission to diagnose, treat, and find a cure for thoracic cancers.

One highlight of the year took place at WCLC in Singapore where our colleagues from Asia were able to gather in person with others from around the world for the first time since the pandemic. The event featured more than 300 speakers, over 6,000 delegates, and more than 100 educational sessions, providing plenty of networking and educational opportunities for attendees.

Our growth did not stop with membership, though. Our publications continued to serve the broad medical community. The **Journal of Thoracic Oncology's** impact factor reached 20.4, fourth among respiratory journals and 13th out of 241 oncology journals. **JTO Clinical and Research Reports** hit its own milestone in 2023 by gaining acceptance into Clarivate's Emerging Source Citation Index, which sets the journal up to receive its first impact factor in June 2024.

The IASLC remained steadfast in support of early-career practitioners through mentoring and our IASLC Academy program. This initiative aimed to cultivate leaders in thoracic oncology by providing education, mentorship, and networking opportunities. Twenty participants attended virtual workshops led by 14 mentors, focusing on career advancement and essential research themes. At WCLC, the cohort explored early-career topics and presented their research projects. They also debuted in The Amazing Case Race, contributing patient case studies for consideration. The top selections were integrated into our inaugural case-based simulation course on **Lung Cancer 360**, the IASLC's new learning management platform.

In 2023, our commitment to education also remained steadfast. We provided diverse learning avenues, including eight webinars, 59 podcasts, and numerous online and offline symposia events. Over 1,000 individuals from 79 countries actively engaged in our webinars, accessing cutting-edge knowledge on thoracic cancer care. Additionally, our 59 podcasts attracted nearly 70,000 listeners, fostering learning across various thematic domains.

Patient advocacy remained an important focus for IASLC in 2023. We continued supporting patient advocates and amplifying their voices through our three STARS programs and our Patient Advocate Education Awards.

Our corporate partners play an important role in supporting IASLC's mission. Their financial support enhances our ability to advance the science of lung cancer and other thoracic malignancies and to provide quality education and networking opportunities for our members. In collaboration with 14 corporate partners, we launched a new initiative in 2023: the IASLC Partners for Thoracic Cancer Care. This initiative seamlessly integrates the expertise of IASLC member experts with industry representatives, fostering collective solutions to major challenges in the field.

In late 2023, the IASLC unveiled the society's five-year strategic plan, redefining the IASLC's mission and vision and setting forth an aggressive blueprint to achieve its goals. The plan was developed over several months and is based on input from the IASLC member survey, IASLC's committees, industry partners, Board of Directors, and staff. The strategic plan redefined the mission statement to "be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care." The strategic pillars, outcomes, aims, and enablers are designed to serve as a roadmap that guides the organization toward a future characterized by groundbreaking discoveries, compassionate care, and transformative impact.

We are excited about the growth IASLC experienced in 2023 and are looking forward to all the new innovations in the field of thoracic cancer care and treatment to come. In 2024, we will remain focused on serving our membership in the hopes of helping to eradicate lung and other thoracic cancers in the future.

All the best



Dr. Karen Kelly
IASLC CEO



Dr. Paul Van Schil
IASLC President



Dr. Heather Wakelee
IASLC Past-President



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Unwavering Achievements & Unity: IASLC's Remarkable Journey in 2023

This year, IASLC soared to unprecedented heights, proudly achieving a historic membership milestone by welcoming over 10,000 members worldwide. This remarkable growth stands as a testament to the global resonance of our mission and the strength in our united community.

Unity in Action:

In-Person Meetings and Member Engagement

Eight in-person meetings took center stage, where our members joined together to share expertise and foster connections. At WCLC in Singapore, colleagues from Asia reunited face-to-face for the first time post-pandemic. These meetings underscored the importance of personal connections, providing platforms for the exchange of invaluable experiences and critical insights in the realm of thoracic cancer.

An important milestone was the initiation of IASLC member focus groups, showcasing our commitment to actively seeking and incorporating member perspectives. The introduction of new technology further facilitated conversational engagement, allowing us to deepen our understanding of member feedback and enhance their overall experience.

Empowering Learning: Lung Cancer 360 and Continuous Education

IASLC's commitment to continuous learning culminated in the launch of **Lung Cancer 360**, a groundbreaking Learning Management System. This platform offers interactive online CME- and non-CME accredited courses, virtual simulations, microlearning modules, webinar recordings, patient advocacy resources, and more—positioning itself as the go-to destination for multidisciplinary online education.



Committee Excellence: Driving Initiatives and Innovation

IASLC's committee members, who represent diverse expertise, play a pivotal role in shaping our society. **With 13 committees spanning patient advocacy to scientific endeavors**, these dedicated individuals actively contribute to the organization's initiatives, from educational content development to scientific advancements including the coming 9th Edition of the TNM Staging Project.

Six new committees are set to launch in the first quarter of 2024, showcasing an overwhelming response from highly qualified candidates globally. This surge in interest emphasizes the global enthusiasm and commitment to advancing our shared mission.

Dedication to Members: Exclusive Benefits and Opportunities

IASLC remains steadfast in demonstrating dedication to our members through exclusive benefits. These include discounted registration fees, complimentary access to the esteemed *Journal of Thoracic Oncology* (JTO), reduced publication fees for *JTO Clinical and Research Reports* (JTO CRR), and access to the valuable IASLC Online Member Directory. Additionally, members enjoy complimentary continuing medical education opportunities, volunteer engagements, and an array of resources, fostering professional growth and collective contribution to our shared mission.

As we reflect on the past year's accomplishments, the IASLC looks ahead with enthusiasm, poised to continue our journey of unity, progress, and thriving together in the fight against thoracic cancers.


join
together
...

stay
together
...

thrive
together
...

IASLC MEMBERSHIP BY THE NUMBERS

MEMBERS BY COUNTRY/REGION



NOTE: Middle East and New Zealand included in ASIA.


TOP 10 COUNTRIES

- 1 CHINA
- 2 UNITED STATES
- 3 JAPAN
- 4 AUSTRALIA
- 5 CANADA
- 6 BRAZIL
- 7 UNITED KINGDOM
- 8 REPUBLIC OF KOREA
- 9 INDIA
- 10 NETHERLANDS

join together ...
 stay together ...
 thrive together ...

IASLC Total Active Members
11,360
2023


MEMBERS BY GENDER




MEMBERS BY AGE




MEMBERS BY PRACTICE LOCATION



MEMBERS BY SPECIALTY



YEARS OF MEMBERSHIP



*Other includes: Pharmacy, Biostatistics, Smoking Cessation, Hematology, Resp. Therapy/Physiotherapy, Patients/Survivors, Caregivers and Unknown.

IASLC 2024-2029 Strategic Plan

IASLC CEO Karen Kelly, MD, unveiled the society’s five-year strategic plan at WCLC 23, redefining the IASLC’s mission and vision and setting forth an aggressive blueprint to achieve its goals. The plan was developed over several months and is based on input from the IASLC member survey, IASLC’s committees, partners, Board of Directors, and staff.

Taken together, the pillars, outcomes, aims, and enablers are designed to serve as a roadmap that guides the organization toward a future characterized by groundbreaking discoveries, compassionate care, and transformative impact.



“ Each pillar stands alone, but what we really like about them is that they flow seamlessly from one to the other. We begin by making scientific discoveries, followed by educating the world, and then confidently implementing the results,”

-Dr. Karen Kelly, IASLC CEO

MISSION

Be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care.

VISION

Conquering lung and other thoracic cancers worldwide in the 21st century.

The 3 Pillars:



Pillar 1: Collaborative Science

Advancing scientific knowledge of thoracic cancers to improve all aspects of prevention and patient care.

Outcome 1: Generate new scientific knowledge that impacts care outcomes through an equitable global lens.

- › **Aim 1:** Maintain an efficient framework for research projects
- › **Aim 2:** Empower our committees to optimally tackle key scientific questions
- › **Aim 3:** Seek out external scientific collaborators who complement gaps in our expertise
- › **Aim 4:** Increase awareness and value of the IASLC brand by leveraging our multidisciplinary scientific knowledge

Outcome 2: Facilitate advancement of member research by increasing resources.

- › **Aim 1:** Expand global creativity and networks across scientific disciplines
- › **Aim 2:** Assemble and uphold a relevant portfolio of scientific resources
- › **Aim 3:** Increase research feasibility and accessibility in Low and Middle-Income Countries (LMIC)

Outcome 3: Include, train, support, and sustain thoracic researchers throughout their career continuum.

- › **Aim 1:** Evolve our global training portfolio for early career investigators
- › **Aim 2:** Grow funding opportunities for early and mid-career investigators
- › **Aim 3:** Increase leadership and recognition opportunities.



Pillar 2: Global Education

Delivering leading edge knowledge worldwide to effectively prevent and combat thoracic cancers.

Outcome 1: Expand accessibility and value of available knowledge.

- › **Aim 1:** Reduce geographic, cultural, and linguistic disparities
- › **Aim 2:** Increase multidisciplinary and specialty content
- › **Aim 3:** Extend credentialing opportunities

Outcome 2: Broaden our educational offerings.

- › **Aim 1:** Increase the number and impact of virtual educational events
- › **Aim 2:** Increase the number and impact of live events at the regional and local level
- › **Aim 3:** Apply innovative learning designs across our educational spectrum

Outcome 3: Provide an accessible and enduring centralized learning repository.

- › **Aim 1:** Establish and support an IASLC Knowledge Hub for lifelong learning
- › **Aim 2:** Ensure a valuable user experience for all stakeholders



Pillar 3: Promote Accessible Multidisciplinary Care

Transforming scientific advancements into actionable patient-centered interventions.

Outcome 1: Establish multidisciplinary, global standards for thoracic malignancy prevention, detection, and care.

- › **Aim 1:** Devise transparent and timely operational processes
- › **Aim 2:** Convene global multidisciplinary expert consensus panels to develop standards
- › **Aim 3:** Communicate the global standards

Outcome 2: Adapt and operationalize global standards for equitable regional and local access and timely care.

- › **Aim 1:** Assemble professional societies, advocacy groups, government agencies, and health system administrators who have interest in optimizing local/regional standards
- › **Aim 2:** Partner with LMIC members, including patients to reduce barriers and create more equitable, accessible, and timely care

Outcome 3: Provide assistance to governmental agencies, enabling them to successfully expand access and increase survival outcomes.

- › **Aim 1:** Identify and cultivate continuous dialogue with international and national health care policy makers
- › **Aim 2:** Bring public and private partners together to address systemic challenges and drive change

“To implement our mission and strategic plan, we need all our members to contribute, and I am really looking forward to collaborating as we move further on this track and keep IASLC the leading organization in thoracic oncology.”

-IASLC President Dr. Paul Van Schil,
Professor of Thoracic and Vascular Surgery,
Antwerp University Faculty of Medicine

SCIENTIFIC AFFAIRS

Every project the IASLC dedicates itself to revolves around lung cancer research across specialties and from around the globe. Whether that novel research is showcased in a new multi-day all-virtual symposium, a podcast or a webinar with expert panelists who can put the data in context, or in an IASLC Lung Cancer News (ILCN) article that discusses the nuances of daily clinical application, we strive to support and promote practice-changing research, providing education to all our volunteers and members.

The IASLC Welcomes Chief Science Officer, Jennifer C. King, PhD

In October 2023 the IASLC welcomed Jennifer King as its new CSO. Dr. King will guide and implement the scientific strategy of the IASLC, support scientific research projects, and manage the Scientific Affairs department.



IASLC FLAGSHIP SCIENTIFIC PROJECTS | 2023

Staging: Improving Lung Cancer Staging through International Collaboration

For over two decades, the IASLC Lung Cancer Staging Project has offered essential guidelines for the TNM categorization of lung cancer, co-published by both the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The IASLC has completed analyzing data for the 9th edition of the TNM Staging System, which for the first time, will include new data elements such as gene mutations, fusions, number alterations, and protein expression levels. The goal of these additional tumor characteristics is to significantly enhance the accuracy of the Staging System, leading to more precise treatment regimens and increased patient survival.

Data collection for the 9th edition closed on December 31, 2021. In this edition, we collected the most data for any cycle of the TNM Staging Project from more than 20 countries:

124,541

LUNG CANCER
CASES

4,585


MESOTHELIOMA
CASES

11,316

THYMIC
MALIGNANCIES
CASES

For the first time, the IASLC piloted a grant program for the Staging Project to provide funding for institutions located in low- to middle-income countries to submit data for the 9th edition. This funding allowed 16 institutions from 12 countries to contribute 9,739 total cases.

Read more about the 9th Edition TNM Staging Classification Publications in the JTO.



Pathologic Response (PR) Initiatives

Overall Goal: To establish pathologic response in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with stages I to III lung cancers.

Neoadjuvant therapies offer unique advantages and challenges in lung cancer treatment. Benefits include early micrometastasis targeting, shortened trial timelines, enhanced detection of metastases, potential improvement in drug delivery and tolerability, and better compliance with subsequent treatments. Challenges include the lack of established protocols for evaluating resected lung cancer specimens after neoadjuvant therapy, uncertain correlations between pathologic response and survival endpoints, and diverse systemic therapies under investigation. The IASLC Neoadjuvant Therapy in Lung Cancers Initiatives aim to address these issues by establishing pathologic response predictors (MPR and pCR) in surgical specimens, potentially predicting long-term clinical benefits for stages I to III lung cancer patients. **Learn more about these initiatives through the IASLC Pathologic Response Initiatives.**

PHASE 0: Organize, Host, and Report Consensus Opinions from the FDA-IASLC Workshop on Neoadjuvant Therapy in Lung Cancers

The IASLC and FDA held a joint international multidisciplinary conference on neoadjuvant therapies in lung cancers in March 2018 to review available data on neoadjuvant therapies in lung cancers, catalog the benefits of neoadjuvant therapies, and identify three next steps to establish neoadjuvant therapy as a standard of care.

Leadership:



Mark G. Kris, MD

William and Joy Ruane Chair in Thoracic Oncology, Weill Medical College of Cornell University

PHASE 1: IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Before undertaking the Pathologic Response (PR) project by the IASLC, there were no established guidelines for processing and evaluating resected lung cancer specimens, and there was a lack of precise definitions for the degree of pathological response following neoadjuvant therapy. These recommendations were published in the Journal of Thoracic Oncology in 2020.

Leadership:



William Travis, MD

Director, Thoracic Pathology
Memorial Sloan Kettering
Cancer Center



Ignacio I. Wistuba, MD

Professor
University of Texas
MD Anderson Cancer Center

PHASE 2: IASLC Reproducibility Study

The IASLC Reproducibility Study aims to determine reproducibility among pathologists of pathologic response determinations using the IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. This study brings together an international cohort of 11 pathologists to evaluate 60-90 NSCLC tumors treated with anti-PD-1 or PD-L1 alone or in combination with chemotherapy or anti-CTLA-4 therapy. **This study was completed in 2023 and culminated in simultaneous publication and results being presented during the closing plenary session at WCLC 2023.**

PHASE 2B: Digital Quantification of Pathologic Response in Neoadjuvant Treated Non-Small Cell Lung Cancer (NSCLC)

In this project, the IASLC will collaborate with PathAI to apply an AI-driven digital pathology assessment of pathologic response and compare this to manual assessments from the IASLC pathologic response interobserver study. This study will support the validation of an AI-powered assessment of pathological response. This project was conceptualized and fully funded in 2021 and is set to conclude with a publication in 2024.

Leadership Phase 2 and 2B:



Wendy Cooper, MD
Associate Professor, Department of
Pathology
Royal Prince Alfred Hospital



Sanja Dacic, MD, PhD, MSc
Vice Chair and Director of
Anatomic Pathology
Yale University Medical School



Keith Kerr, MD, FRCPath
Professor of Pulmonary Pathology
University of Aberdeen, School of
Medicine and Dentistry



William Travis, MD
Director, Thoracic Pathology
Memorial Sloan Kettering Cancer
Center



Ignacio I. Wistuba, MD
Professor
University of Texas
MD Anderson Cancer Center

PHASE 3: Lung Cancer Neoadjuvant Trial Endpoint Database (LCNTED)


In the final phase of the IASLC Neoadjuvant Therapies in Lung Cancer Initiative, a multidisciplinary group will identify the data necessary, collect the required information from neoadjuvant trials worldwide, and execute the statistical analyses to support the use of pathologic response as a determinant of long-term outcomes. This process has been accomplished in the CTNeoBC-pooled analysis project analyzing neoadjuvant trials in breast cancers.

Following the lead of CTNeoBC in breast cancers, Phase 3 of the LCNTED initiative will:

1. Establish the association between pathologic response and event-free survival (EFS) and overall survival (OS);
2. Establish the definition of pathologic response, including MPR and CPR, that correlates best with long-term outcomes;
3. Identify the lung cancer subtypes in which pathologic response best correlates with long-term outcomes; and
4. Assess whether increases in pathologic response between treatment groups predict improved EFS and OS.

An initiative of this magnitude and importance requires the collaboration of multiple partners and stakeholders to make meaningful progress. Therefore, this initiative will bring together the IASLC membership, FDA regulators, and various leading industry partners with phase 3 neoadjuvant trials in lung cancer, who all share the common goal of eliminating lung cancer as a cause of death. The IASLC will begin database design in 2024, data collection as early as 2024, with the project concluding in 2028.

Leadership:




Paul Bunn, MD
Professor and Dudley Endowed Chair
University of Colorado Denver
Medical Campus



Mark G. Kris, MD
William and Joy Ruane Chair
in Thoracic Oncology
Weill Medical College of
Cornell University



Yu Shyr, PhD, Director
Vanderbilt Center for
Quantitative Sciences
Vanderbilt Technologies for
Advanced Genomics Analysis
and Research Design



ELIC

EARLY LUNG IMAGING CONFEDERATION

The vision of the IASLC is to **Conquer Thoracic Cancers Worldwide in the 21st Century**. One of the best ways to fulfill this vision, beyond risk reduction, is to detect these cancers at an early stage. Effective low-dose computed tomography (LDCT) screening is critical to detecting and diagnosing lung cancer early and thus increasing survival.

The Early Lung Imaging Confederation (ELIC) is an international alliance of collaborating individuals and institutions who share a vision to develop a globally distributed, privacy-secured, thoracic images database and computational analysis environment. The fundamental goal of the ELIC database is to support the development of deep learning methods and artificial intelligence (AI) approaches that can detect lung cancer and other diseases early, characterize small pulmonary nodules and surrounding structures and measure responsiveness to therapeutic interventions using thoracic CT images.

In 2023, ELIC fully completed Phase II of the project and published the results in the Journal of Thoracic Oncology article “The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.” The collaborating researchers will now query the database with AI algorithms.

For more information about ELIC, please visit <https://iaslc-elic.org/>.



Stephen Lam, MD, FRCPC
British Columbia
Cancer Research
Vancouver, Canada



Witold Rzyman, MD
Medical University
of Gdansk
Gdansk, Poland



Kazuto Ashizawa, MD
Nagasaki University
Nagasaki, Japan



Ugo Pastorino, MD
IRCCS National Cancer
Institute Foundation
Milan, Italy



Claudia Henschke, MD, PhD
Mount Sinai, New York, NY,
United States



Annette McWilliams, MD
Fiona Stanley Hospital
Perth, Australia



Bruno Hochegger, MD, PhD
Federal University of Health
Sciences of Porto Alegre
Porto Alegre, Brazil



IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update

In 2023, IASLC began work in partnership with the Partners in Thoracic Cancer Care Consortium of corporate partners to conduct a new global survey of both IASLC members and non-members to determine biomarker testing uptake for lung cancer among healthcare providers around the world and to take a deeper dive into the barriers to adoption of biomarker testing. The first IASLC survey on global biomarker testing was completed in 2018 and has been published in *Journal of Thoracic Oncology*. However, the global state of biomarker testing and global implementation has changed significantly during the past five years. The survey will be deployed in 2024, and IASLC anticipates that the learnings will lead to a subsequent project on devising an implementation toolkit for biomarker testing.

“There have been exciting advances in biomarker-driven therapies for individuals with lung cancer since the time of the first IASLC survey,” said Dr. Mathew Smeltzer, the lead epidemiologist for the 2020 and 2024 surveys. “The new survey will help us understand how biomarker testing practices have evolved for late-stage lung cancer, the state of testing in early-stage lung cancer, and more details about barriers to optimal testing that could inform solutions.”

General Lung Cancer Publications

IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer

Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V, Rami-Porta R; Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions. *J Thorac Oncol.* 2023 May;18(5):564-575. doi: 10.1016/j.jtho.2023.01.088. Epub 2023 Feb 10.

Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee

Berg CD, Schiller JH, Boffetta P, Cai J, Connolly C, Kerpel-Fronius A, Kitts AB, Lam DCL, Mohan A, Myers R, Suri T, Tammemagi MC, Yang D, Lam S; International Association for the Study of Lung Cancer (IASLC) Early Detection and Screening Committee. *J Thorac Oncol.* 2023 Oct;18(10):1277-1289. doi: 10.1016/j.jtho.2023.05.024. Epub 2023 Jun 3.

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy

Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabasedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA Jr, Kris MG, Belani CP, Kelly K, Wistuba I; IASLC Pathology Committee. *J Thorac Oncol.* 2023 Oct;18(10):1290-1302. doi: 10.1016/j.jtho.2023.07.017. Epub 2023 Sep 12.



The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors

Wentao Fang, MD, Nicolas Girard, MD, Vanessa Cilento, MPH, Emily Goren, PhD, MS, Daniel Dibaba, PhD, MPH, Enrico Ruffini, MD, Usman Ahmad, MD, Sarit Appel, MD, Andrea Bille, MD, Souheil Boubia, MD, Cecilia Brambilla, MD, Ayten Kayi Cangir, MD, Frank Detterbeck, MD, Conrad Falkson, MbChB., MD, Pier Luigi Filosso, MD, Giuseppe Giaccone, MD,, Francesco Guerrera, MD, James Huang, MD, Maurizio Infante, MD, Dong Kwan Kim, MD, Marco Lucchi, MD, Mirella Marino, MD, Edith M. Marom, MD, Andrew G. Nicholson, MD, Meinoshin Okumura, MD, Ramon Rami-Porta, MD, Andreas Rimner, MD, Charles B. Simone II, MD, Hisao Asamura, MD, and Members of the Staging and Prognostic Factors Committee, Members of the Advisory Boards and Participating Institutions of the Thymic Domain.

Natural History and Real-world Treatment Outcomes for Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutation: An IASLC-ASCO CancerLinQ Study


Madhusmita Behera, Renjian Jiang, Zhonglu Huang, Becky Bunn, Murry W. Wynes, Jeffrey Switchenko, Giorgio V. Scagliotti, Chandra P. Belani, Suresh S. Ramalingam, J Thoracic Oncology, October 18, 2023

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Van Schil PE, Asamura H, Nishimura KK, Rami-Porta R, Kim YT, Bertoglio P, Cangir AK, Donington J, Fang W, Giroux D DJ, Lievens Y, Liu H, Lyons G, Sakai S, Travis WD, Ugalde P, Jeffrey Yang CF, Yotsukura M, Detterbeck F; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. J Thorac Oncol. 2023 Dec 7: S1556-0864(23)02411-5. doi: 10.1016/j.jtho.2023.12.006. Online ahead of print.

Perspective on Management of Low-Dose Computed Tomography Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening. From the International Association for the Study of Lung Cancer Early Detection and Screening Committee

Claudia Henschke, MD, Rudolf Huber, MD, Long Jiang, MD, Dawei Yang, MD, Milena Cavic, PhD, Heidi Schmidt, MD, Ella Kazerooni, MD, Javier J. Zulueta, MD, Ricardo Sales dos Santos, MD, Luigi Ventura, MD. And members of the Diagnostics Working Group, Early Detection and Screening Committee. Published: November 16, 2023 DOI



The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Huang J, Osarogiagbon RU, Giroux DJ, Nishimura KK, Bille A, Cardillo G, Detterbeck F, Kernstine K, Kim HK, Lievens Y, Lim E, Marom E, Prosch H, Putora PM, Rami-Porta R, Rice D, Rocco G, Rusch VW, Opitz I, Vasquez FS, Van Schil P, Jeffrey Yang CF, Asamura H; Members of the Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain. *J Thorac Oncol.* 2023 Oct 20:S1556-0864(23)02310-9. doi: 10.1016/j.jtho.2023.10.012. Online ahead of print.



Thymic Publications

The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic Epithelial Tumors for the Forthcoming Ninth Edition of the TNM Classification of Malignant Tumors

Marom EM, Fang W, Ruffini E, Detterbeck F, Ahmad U, Appel S, Bille A, Boubia S, Brambilla C, Cilento V, Cangir AK, Falkson C, Filosso PL, Giaccone G, Girard N, Goren E, Guerrero F, Huang J, Infante M, Kim DK, Lucchi M, Marino M, Nicholson AG, Okumura M, Rami-Porta R, Rimner A, Simone CB 2nd, Asamura H; Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards and Participating Institutions. *J Thorac Oncol.* 2023 Dec;18(12):1672-1688. doi: 10.1016/j.jtho.2023.09.001. Epub 2023 Sep 9.

The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: sRuffini E, Huang J, Cilento V, Goren E, Detterbeck F, Ahmad U, Appel S, Bille A, Boubia S, Brambilla C, Cangir AK, Falkson C, Fang W, Filosso PL, Giaccone G, Girard N, Guerrero F, Infante M, Kim DK, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Rami-Porta R, Rimner A, Simone CB 2nd, Asamura H; Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions. *J Thorac Oncol.* 2023 Dec;18(12):1655-1671. doi: 10.1016/j.jtho.2023.09.002. Epub 2023 Sep 9.

Mesothelioma Publications

The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma

Wolf AS, Rosenthal A, Giroux DJ, Nowak AK, Bille A, de Perrot M, Kindler HL, Rice D, Opitz I, Rusch VW, Pass HI; Members of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee; Advisory Board, and Participating Institutions. *J Thorac Oncol.* 2023 Dec;18(12):1689-1702. doi: 10.1016/j.jtho.2023.08.005. Epub 2023 Aug 9.

The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Enrico Ruffini, MD, James Huang, MD, Vanessa Cilento, MPH, Emily Goren, PhD, MS, Frank Detterbeck, MD, Usman Ahmad, MD, Sarit Appel, MD, Andrea Bille, MD, Souheil Boubia, MD, Cecilia Brambilla, MD, Ayten Kayi Cangir, MD, Conrad Falkson, MBChB., Wentao Fang, MD, Pier Luigi Filosso, MD, Giuseppe Giaccone, MD, Nicolas Girard, MD, Francesco Guerrero, MD, Maurizio Infante, MD, Dong Kwan Kim, MD, Marco Lucchi, MD, Mirella Marino, MD, Edith M. Marom, MD, Andrew G. Nicholson, MD, Meinoshin Okumura, MD, Ramon Rami-Porta, MD, Andreas Rimner, MD, Charles B. Simone II, MD, Hisao Asamura, MD, Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions, *J Thorac Oncol.* 2023 December. P1655-1671 Volume 18, Issue 12.

The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Wentao Fang, MD, Nicolas Girard, MD, Vanessa Cilento, MPH, Emily Goren, PhD, MS, Daniel Dibaba, PhD, MPH, Enrico Ruffini, MD, Usman Ahmad, MD, Sarit Appel, MD, Andrea Bille, MD, Souheil Boubia, MD, Cecilia Brambilla, MD, Ayten Kayi Cangir, MD, Frank Detterbeck, MD, Conrad Falkson, MbChB., MD, Pier Luigi Filosso, MD, Giuseppe Giaccone, MD, Francesco Guerrera, MD, James Huang, MD, Maurizio Infante, MD, Dong Kwan Kim, MD, Marco Lucchi, MD, Mirella Marino, MD, Edith M. Marom, MD, Andrew G. Nicholson, MD, Meinoshin Okumura, MD, Ramon Rami-Porta, MD, Andreas Rimner, MD, Charles B. Simone II, MD, Hisao Asamura, MD, and Members of the Staging and Prognostic Factors Committee, Members of the Advisory Boards and Participating Institutions of the Thymic Domain. *J Thoracic Oncology*, Sept. 26, 2023

Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer

Stephen Lam, MD, FRCPC, Chunxue Bai, MD, PhD, David R. Baldwin, MD, FRCPC, Yan Chen, MD, Casey Connolly, MPH, Harry de Koning, MD, PhD, Marjolein A. Heuvelmans, MD, PhD, Ping Hu, ScD, Ella A. Kazerooni, MD, MS, Harriet L. Lancaster, BScHons, Georg Langs, PhD, Annette McWilliams, M.B.B.S., FRACP, Raymond U. Osarogiagbon, M.B.B.S., FACP, Matthijs Oudkerk, MD, PhD, Matthew Peters, M.B.B.S., Hilary A. Robbins, PhD, Liora Sahar, PhD, Robert A. Smith, PhD, Natthaya Triphuridet, MD, PhD, John Field, PhD, FRCPath, *J. Thorac Oncology*, July 22, 2023

The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

Stephen Lam, MD, FRCPC, Murry W. Wynes, PhD, Casey Connolly, MPH, Kazuto Ashizawa, MD, PhD, Sukhinder Atkar-Khattra, BSc, Chandra P. Belani, MD, Domenic DiNatale, PhD, Claudia I. Henschke, MD, PhD, Bruno Hochhegger, MD, PhD, Claudio Jacomelli, PhD, Małgorzata Jelitto, MD, Artit Jirapatnakul, PhD, Karen L. Kelly, MD, Karthik Krishnan, MS, Takeshi Kobayashi, MD, PhD, Jacqueline Logan, BaN, Juliane Mattos, PhD, John Mayo, MD, FRCPC, Annette McWilliams, M.B.B.S., FRACP, Tetsuya Mitsudomi, MD, PhD, Ugo Pastorino, MD, Joanna Polańska, PhD, Witold Rzyman, MD, PhD, Ricardo Sales dos Santos, MD, PhD, Giorgio V. Scagliotti, MD, PhD, Heather Wakelee, MD, David F. Yankelevitz, MD, John K. Field, PhD, FRCPath., James L. Mulshine, MD, Ricardo Avila, MS, *J. Thoracic Oncology*, August 15, 2023



IASLC 2023

CONFERENCES AND EVENTS



IASLC strives to provide quality education and networking opportunities to our members, and 2023 was no exception. More than 7,800 delegates met in person and virtually to learn, collaborate and network throughout 2023.

As we move forward into 2024, we plan to continue providing both in-person and on-demand options for our events, allowing everyone working to defeat thoracic cancers and malignancies access to the latest information and education in the field.



2023 Latin America Conference on Lung Cancer

JANUARY 25-27, 2023 | MONTEVIDEO, URUGUAY

Conference Co-Chairs: LATAM Steering Committee:

Carlos Barrios
Clarissa Matthias
Luis Ubillos
Mario Varangot

Luiz Raez
Christian Rolfo
Edgardo Santos



219
REGISTRATIONS

25
COUNTRIES

6
SPONSORS/
EXHIBITORS

2
SYMPOSIA

26
SCIENTIFIC
SESSIONS

53
CHAIRS/
SPEAKERS

53
POSTERS

109
ABSTRACTS



2023 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 22-25, 2023 | SANTA MONICA, CALIFORNIA

Conference Co-Chairs:

Charu Aggarwal
Paul Bunn
Joel Neal
Lecia Sequist



758
IN-PERSON
REGISTRATIONS

248
VIRTUAL
REGISTRATIONS

198
CHAIRS/SPEAKERS

16
SPONSORS/EXHIBITORS

33
COUNTRIES

15
SCIENTIFIC SESSIONS

4
SYMPOSIA

35
POSTERS

48
ABSTRACTS



2023 HOT TOPIC MEETING: SMALL CELL LUNG CANCER

APRIL 5-7, 2023 | NEW YORK, NEW YORK

Conference Co-Chairs:

Charles Rudin
David MacPherson
Kathryn Simpson
Kate Sutherland
Alvaro Quintanal-Villalonga



268
REGISTRATIONS

50
FACULTY

8
SCIENTIFIC
SESSIONS

17
POSTERS

5
INDUSTRY
SUPPORTERS

22
COUNTRIES



2023 World Conference on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

Conference Co-Chairs



Fiona Hegi-Johnson



Pyng Lee



Chee Lee

WCLC 2023 AWARD WINNERS

Each year, the IASLC honors professionals who have made major contributions to the field of thoracic cancers with its Distinguished Service Awards. The association distributes awards that recognize lifetime achievement in specific areas of practice with the most significant honors—the **IASLC Distinguished Service Awards**.

JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD	ADI F. GAZDAR IASLC MERIT AWARD	PAUL A. BUNN, JR. SCIENTIFIC AWARD	MARY J. MATTHEWS PATHOLOGY/ TRANSLATIONAL RESEARCH AWARD
William Evans Canada	Myung-Ju Ahn Republic of Korea	Suresh Ramalingam USA	Fernando Lopez-Rios Spain

IASLC DISTINGUISHED SERVICE AWARD WINNERS

2023 Lectureship Award Winners

The IASLC Lectureship Awards are focused in the areas of radiation oncology, medical oncology, small cell lung cancer, nursing/allied health, translational research, thoracic surgery, staging, and tobacco control.



Clifton F. Mountain Lectureship Award for Staging
Navneet Singh, India



IASLC Lectureship Award for Tobacco Control and Smoking Cessation
Silvia Novello, Italy



Tsuguo Naruke Lectureship Award for Surgery
Alan Sihoe, Hong Kong



Daniel C. Ihde Lectureship Award for Medical Oncology
D. Ross Camidge, USA



Fred R. Hirsch Lectureship Award for Translational Research
Wendy Cooper, Australia



IASLC Lectureship Award for Nurses and Allied Health Professionals
Melissa Culligan, USA




Heine H. Hansen Lectureship Award for Small Cell Lung Cancer
Jie Wang, China



Robert J. Ginsberg Lectureship Award for Surgery
Jessica Donington, USA



James D. Cox Lectureship Award for Radiation Oncology
Rafal Dziadziszko, Poland



5,622 DELEGATES

93 COUNTRIES

63 EDUCATION & OTHER AWARDS

20 INDUSTRY SYMPOSIA

55 SUPPORTERS & EXHIBITORS

22 ADVISORY BOARD MEETINGS

1,831 ABSTRACTS

411 INVITED FACULTY

1,158 POSTERS & EPOSTERS

WCLC 2023 KEY MEDIA HIGHLIGHTS



Recipient of the 4th Annual Silver Healthcare Digital Marketing Award for Outstanding Public Relations Event

19
NEWS RELEASES

4
PRESS BRIEFINGS

126
COUNTRIES FILED STORIES

5
LUNG CANCER CONSIDERED PODCASTS

69,100
TOTAL MEDIA MENTIONS

186
REGISTERED MEDIA

WCLC 2023 Highlights





IASLC 2023 CT SCREENING SYMPOSIUM
FOREFRONT ADVANCES IN
LUNG CANCER SCREENING
SEPTEMBER 9, 2023 | SINGAPORE



The CT Screening Symposium was a one-day, immersive, in-person event featured at WCLC 2023 focused on lung cancer screening technologies and best practices. Using a mix of live educational presentations, real-time expert discussions, and interactive live Q&A opportunities, the Symposium addressed topics relevant to our international audience such as screening implementation models, which patients should be screened, and practical application of AI and advanced technologies in lung screening. Faculty provided anecdotal experience and reviewed current data highlighting successes and addressing barriers to implementing more uniform and effective lung cancer screening worldwide. The 2023 CT Screening Symposium saw its largest attendance to date with 267 in-person registrants.


SESSION CO-CHAIRS

Stephen Lam,
Canada

Marjolein Heuvelmans,
Netherlands

Pyng Lee,
Singapore

Chi-Fu Jeffrey Yang,
USA



**2023 HOT TOPIC IN BASIC & TRANSLATIONAL SCIENCE:
RESISTANCE TO IO IN NSCLC**

NOVEMBER 10-12, 2023 | BRUSSELS, BELGIUM



Conference Co-Chairs:

Joachim Aerts
Roberto Ferrara
Kellie Smith

116
REGISTRATIONS

31
CHAIRS/SPEAKERS

30
SUBMITTED
ABSTRACTS

8
ORAL
ABSTRACTS

10
POSTERS

20
COUNTRIES

2
SPONSORS/
EXHIBITORS



**2023 North America
Conference on
Lung Cancer**

DECEMBER 1-3, 2023 | CHICAGO, ILLINOIS

Conference Co-Chairs:

Mohamed Abazeed
Christine Bestvina
Loretta Erhunmwunsee
Jyoti Patel
Everett Vokes



570
REGISTRATIONS

63
CHAIRS/SPEAKERS

139
SUBMITTED
ABSTRACTS

6
ORAL
ABSTRACTS

126
POSTERS

13
COUNTRIES

19
SPONSORS

EDUCATION: WEBINARS, GRANT-FUNDED ACTIVITIES



	2023 ACTIVITIES	DESCRIPTION/SYNOPSIS	ATTENDEES
A	Webinars		
1	6-14-23 <i>The Impact of Lung Cancer on Intimate Relationships</i> NAHP Committee	Changes in intimacy and sexual relationships often go unaddressed and untreated in people with lung cancer and it impacts emotional health, well-being and quality of life. This webinar prepared clinicians to discuss intimacy and sexual relationships and to help people with cancer and their partners access the support they need.	24
2	8-22-23 <i>Emerging ADCs in Advanced Lung Cancer Treatment</i> Education Committee	Gaps and learning needs exist whenever novel agents are introduced into treatment. Experience with the use of ADCs is limited; therefore, this webinar educated health care providers on the use of these agents and the management of associated toxicities.	186
3	8-29-23 <i>Approaches of Radiotherapy for Small Cell Lung Cancer</i> ART Committee	This webinar addressed controversies in the way radiation therapy is used to treat both limited and extensive stage small cell lung cancer, including thoracic radiation, hippocampal sparing prophylactic cranial radiation, and the treatment of brain metastases. It also addressed the evolving role of radiotherapy in the context of new chemo-immunotherapy treatments	173
4	11-8-23 <i>2023 Radiation Oncology Updates</i> Education and ART Committees	Updates and information related to the use of radiation is under-represented in lung cancer education initiatives, which are dominated by systemic therapies. As radiation continues to be an important treatment across all stage and subtypes of lung cancer, this webinar served to address some of the gaps for both radiation and non-radiation oncology healthcare professionals.	144
5	7-6-23 <i>2023 ASCO Highlights</i> Education Committee	An increasing number of novel therapeutic strategies have been introduced into the treatment of non-small cell lung cancer. Especially during the ASCO 2023, many pivotal trials were reported and were described and discussed in detail in this webinar.	157
6	10-13-23 <i>2023 WCLC Highlights</i> Education Committee	Topics of discussion included EGFRm advanced NSCLC (FLAURA2), stereotactic ablative radiotherapy (I-SABR study), surgical outcomes in resectable NSCLC (AEGEAN), cardiovascular effects of immunotherapy, PD-L1 tumor cell scoring, and the 9th edition of TNM Classification for lung cancer.	190
7	11-15-23 <i>2023 ESMO Highlights</i> Education Committee	IASLCs Education Committee presented a one-hour live session synthesizing lung cancer research presented at the October meeting of the European Society for Medical Oncology (ESMO) 2023 Congress. This webinar addressed clinicians' need to keep abreast of current research and future trends to inform clinical practice.	122
8	12-7-23 <i>2023 NACLC Highlights</i> Education Committee	The IASLC Education committee presented a one-hour live session focused on the review and discussion of the most impactful and important topics presented at the IASLC North American Conference on Lung Cancer (NACLC) meeting.	92


	2023 ACTIVITIES	DESCRIPTION/SYNOPSIS	ATTENDEES
B	Grant-Funded		
1	<p>KOL Knockout™: Cancer Pain Management Edition (Live and Enduring activities) <i>Funded by the Opioid Analgesic REMS Program Companies</i></p>	<p>Using Evolve Medical Education's KOL Knockout™ format, the virtual symposium focused on the challenges of managing pain in patients with cancer. Key opinion leaders (KOLs) were challenged by the host to diagnose and manage patient scenarios with varying levels of difficulty. After each case presentation, learners voted for the KOL they think answered best, and the moderator declared a match winner at the conclusion.</p> <p>There was learning, laughter, and only one KOL left standing!</p>	127
2	<p>Review of Diagnostic and Therapeutic Implications of EGFR Exon20 Insertions in Metastatic Non-Small Cell Lung Cancer (Live and Enduring activities) <i>Funded by Janssen</i></p>	<p>Precision Oncology aims to use cancer treatments that are targeted to individual patients based on genetic, biomarker, phenotypic, or psychosocial characteristics. Technical advances in genome sequencing and the implementation of next generation sequencing (NGS) in clinical oncology are paving the way for this individualized patient therapy based on molecular profiles. In this context, physicians must be aware of the clinical evidence behind the NGS tests available, so they can use them at the right moment.</p> <p>This review focused on the use of NGS testing for mutations in the epidermal growth factor receptor (EGFR) gene, which is the most common targetable genomic driver in non-small cell lung cancer (NSCLC).</p>	114
3	<p>2023 NACLC Symposia: The Basics of Pain Management for Cancer Patients from Diagnosis to Palliative Care: Thoracic Cancer Edition (Live and Enduring activities) <i>Funded by the Opioid Analgesic REMS Program Companies</i></p>	<p>The symposium focused on the challenges of managing thoracic cancer pain using a didactic, interactive case-based format. Patient advocates joined the discussion to give a patient perspective on effective cancer pain management.</p>	26
4	<p>2023 IASLC Academy Amazing Case Race: Thoracic Cancer Simulation Course <i>Funded by Janssen and AbbVie</i></p>	<p>This enduring activity took learners through various thoracic oncology case-based simulations created by the 2023 winners of the IASLC Academy's Amazing Case Race.</p>	149

	2023 Activities	Description/Synopsis	Attendees
C	2023 Academy		
1	WCLC Workshop	The IASLC Academy supports early-career physicians and researchers. The year-long program is taught by a multi-disciplinary group of leaders in the field, and participants receive one-on-one mentoring as they complete a project and explore topics related to career development and research.	20 Awardees 14 Faculty
2	Amazing Case Race	Members of the 2023 IASLC Academy participated in the first Amazing Case Race event. Each participant produced a case summary based on real-life patients. WCLC attendees voted for their favorite case summary, and the five cases with the most votes were included in the IASLC's first case-based simulation course.	20
D			
1	LMS – soft launch	On December 19, 2023, the IASLC Board of Directors, Committee and NACLC attendees were provided with an early preview of IASLC's new online learning management system, Lung Cancer 360.	31
E			
1	Podcast	Lung Cancer Considered, the official IASLC podcast, provides a platform for engaging conversations with internationally recognized researchers, healthcare professionals, patients and advocates influencing the landscape of thoracic cancers.	68,994 Listeners

2023 IASLC WEBINARS


Webinars are an important part of IASLC's offerings, providing education and insight to those in the thoracic cancer community. In 2023, 1,063 people attended eight IASLC webinars, representing multiple specialties, geographic regions, and both IASLC members and non-members.

Representing 79 Countries:




Region	#Attendees
North America	
US	26.43%
Canada	6.19%
Mexico	1.50%
Costa Rica	0.66%
Europe	
United Kingdom	5.72%
Germany	2.72%
Spain	2.53%
Italy	2.34%
Portugal	2.25%
Great Britain	1.69%
Switzerland	1.59%
Netherlands	1.59%
Belgium	1.59%
Norway	1.03%
Hungary	0.94%
Denmark	0.84%
Greece	0.75%
France	0.66%
Austria	0.47%
Slovenia	0.47%
Malta	0.37%
Bosnia	0.28%
Poland	0.28%
Serbia	0.19%
Sweden	0.19%
Czech Republic	0.10%
Ukraine	0.09%
Lithuania	0.09%
Estonia	0.09%
Albania	0.09%
Moldova	0.09%
Ireland	0.09%
Monaco	0.09%
Cyprus	0.09%
Bulgaria	0.09%
Asia	
Japan	6.94%
India	1.97%
Turkey	1.87%
Singapore	1.59%
Hong Kong	1.22%
Egypt	1.12%
Russia	1.10%
Bangladesh	1.03%
China	1.03%
Taiwan	0.94%
Korea	0.94%
Vietnam	0.84%
Indonesia	0.66%
Pakistan	0.66%
Armenia	0.37%
Romania	0.37%
Nepal	0.28%
Philippines	0.28%
Thailand	0.28%
Jordan	0.28%
Israel	0.19%
Palestinian Territories	0.19%
Azerbaijan	0.19%
Malaysia	0.19%
Saudi Arabia	0.19%
Iraq	0.19%
Myanmar	0.09%
South America	
Brazil	2.16%
Chili	0.94%
Peru	0.84%
Colombia	0.75%
Argentina	0.66%
Trinidad	0.56%
Uruguay	0.19%
Venezuela	0.09%
Ecuador	0.09%
Africa	
South Africa	0.94%
Nigeria	0.56%
Congo	0.28%
Algeria	0.28%
Morocco	0.28%
Gambia	0.09%
Oceania	
Australia	1.59%
New Zealand	0.37%
Grand Total	100.00%

Sum of Attendees by General Profession




Sum of Attendees by Specialties




JUNE

IASLC **WEBINARS**


THE IMPACT OF LUNG CANCER ON INTIMATE RELATIONSHIPS




June 13, 2023
5pm MST




ACCME ACCREDITED



Dr. Narjust Florez



Dr. Stephanie Ejegi-Memeh



Jill Feldman

Brought to you by IASLC's Nurses & Allied Health Professionals Committee

#LCWEBINARS

Presented by the NAHP Committee

Changes in intimacy and sexual relationships often go unaddressed and untreated in people with lung cancer, and it impacts emotional health, well-being and quality of life. This webinar prepared clinicians to discuss intimacy, sexual relationships and help people with cancer and their partners access the support that they need.

Moderator: Maria Ftanou

Presenters: Stephanie Ejegi-Memeh, Narjust Florez, Jill Feldman

JULY

IASLC **WEBINARS**

ASCO 2023 HIGHLIGHTS



July 6, 2023
6am MST



ACCME ACCREDITED



Dr. Hidehito Horinouchi



Dr. Jyoti Patel



Dr. Navneet Singh



Dr. Stephanie Saw

Brought to you by IASLC's Education Committee

#LCWEBINARS

Presented by the Education Committee

An increasing number of novel therapeutic strategies have been introduced into the treatment of non-small cell lung cancer. Especially during the ASCO 2023, many pivotal trials were reported and were described and discussed in detail in this webinar.

Moderators: Hidehito Horinouchi

Panelists: Navneet Singh, Stephanie Saw, Jyoti Patel

AUGUST

IASLC **WEBINARS**

EMERGING ADCs & THEIR ROLE IN ADVANCED LUNG CANCER TREATMENT



August 22, 2023
8am MST



ACCME ACCREDITED



Dr. Antoinette Wozniak



Dr. Benjamin Levy



Dr. Daniel Tan



Dr. Alona Zer

Brought to you by IASLC's Education Committee

#LCWEBINARS

Presented by the Education Committee

Gaps and learning needs exist whenever novel agents are introduced into treatment. Experience with the use of ADCs is limited; therefore, this webinar educated health care providers on the use of these agents and the management of associated toxicities.

Moderator: Antoinette Wozniak

Presenters: Daniel Tan, Benjamin Levy, Alona Zer

IASLC **WEBINARS**

CURRENT APPROACHES AND FUTURE DIRECTIONS IN RADIOTHERAPY FOR SMALL CELL LUNG CANCER



Dr. Corinne Faivre-Finn | Dr. Kristin Higgins | Dr. Antonin Levy

August 29, 2023
11am MST



Brought to you by IASLC's Advanced Radiation Technology Committee

#LCWEBINARS

Presented by the Make it Advanced Radiation Technology Committee

This webinar addressed controversies in the way radiation therapy is used to treat both limited and extensive stage small cell lung cancer, including thoracic radiation, hippocampal sparing prophylactic cranial radiation, and the treatment of brain metastases. It also addressed the evolving role of radiotherapy in the context of new chemo-immunotherapy treatments.

Moderator: Corinne Faivre-Finn

Presenters: Kristin Higgins, Antonin Levy

OCTOBER

IASLC **WEBINARS**

2023 WCLC HIGHLIGHTS



Dr. Navneet Singh | Dr. Clarissa Baldotto | Dr. Lizza Hendricks | Dr. Christian Rolfo

Friday
October 13, 2023
7am MDT



Brought to you by IASLC's Education Committee

#LCWEBINARS

Presented by the Education Committee

Topics of discussion included EGFRm advanced NSCLC (FLAURA2), stereotactic ablative radiotherapy (I-SABR study), surgical outcomes in resectable NSCLC (AEGEAN), cardiovascular effects of immunotherapy, PD-L1 tumor cell scoring, and the 9th edition of TNM Classification for lung cancer.

Moderator: Navneet Singh

Panelists: Christian Rolfo, Clarissa Baldotto, Lizza Hendricks

NOVEMBER

IASLC **WEBINARS**

2023 RADIATION ONCOLOGY UPDATE



Alex Louie | Houda Bahig | Fiona McDonald | Pranshu Mohindra

Wednesday
November 11, 2023
11am EST



Brought to you by IASLC's Education Committee/Advanced Radiation Technology Committee

#LCWEBINARS

Presented by the Education, CME, and Advanced Radiation Technology Committees

This session focused on providing updates and new developments in Radiation Oncology for lung cancers. Highlights included impactful studies from the recent WCLC and ASTRO annual scientific meetings, as well as other new practice-changing radiation publications.

Moderator: Alexander Louie

Panelists: Pranshu Mohindra, Houda Bahig, and Fiona McDonald



WEBINARS

2023 ESMO HIGHLIGHTS



Pilar Garrido

Bartomeu Massuti

Helena Linardou

Telma Sequeira



Brought to you by IASLC's Education Committee

#LCWEBINARS

This webinar synthesized lung cancer research presented at the October meeting of the European Society for Medical Oncology (ESMO) 2023 Congress. It addressed clinicians' need to keep abreast of current research and future trends to inform clinical practice and change the standard practice of care.

Moderator: Pilar Garrido

Presenters: Bartomeu Massuti, Telma Sequeira, and Helena Linardou

DECEMBER



WEBINARS

2023 NACLC HIGHLIGHTS



Dr. Luis Raez

Dr. Christine Bestvina

Dr. Mohamed Abazeed

Dr. Jyoti Patel



Brought to you by IASLC's Education Committee

#LCWEBINARS

Presented by the Education Committee

This one-hour webinar focused on reviewing and discussing the most impactful and important topics presented at the recent IASLC 2023 North American Conference on Lung Cancer.

Moderator: Dr. Luis Raez

Presenters: Christine Bestvina, Mohamed Abazeed, and Jyoti Patel

Journal of Thoracic Oncology

A Beacon of Excellence

The *Journal of Thoracic Oncology (JTO)* continues to be a leading source of education and information covering all facets of thoracic malignancies. The JTO offers a comprehensive array of content, including original research, reviews, and opinion pieces, catering to a diverse audience that includes epidemiologists, statisticians, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and research scientists with a specific focus on thoracic oncology.

ELEVATING INFLUENCE: A REMARKABLE JOURNEY

In recent years, the JTO has experienced a substantial increase in its impact factor, a key metric reflecting its influence within the field. The 2022 impact factor reached an impressive 20.4, showcasing a notable rise from 20.121 in 2021. This surge in impact factor propels the JTO to the 4th position among 65 respiratory system journals and the 13th position among 241 oncology journals. This remarkable ascent underscores the journal's growing significance and impact on the global stage.


EMPOWERING THE THORACIC ONCOLOGY COMMUNITY

As the JTO continues to evolve, it remains committed to empowering the thoracic oncology community with cutting-edge research, insights, and perspectives. The sustained growth in impact factor is a testament to the journal's dedication to excellence, providing a platform that resonates with a broad spectrum of professionals dedicated to advancing knowledge and care in thoracic malignancies.

“JTO’s impact factor has more than quadrupled from **5.040 in 2015 to 20.4 in 2022**. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals. More importantly, the impact factor of other journals in thoracic oncology or surgery fell in 2022. This achievement is a testament to the exemplary work of our editorial board and our managing editor, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology.”



-Alex A. Adjei, MD, PhD, FACP
Editor-in-Chief



Special Series and New Initiatives

SPECIAL SERIES	DESCRIPTIONS
Editor's Choice	<ul style="list-style-type: none"> Monthly featured JTO articles – free access for 3 months after online publication
Lung Cancer Worldwide Series	<ul style="list-style-type: none"> 45 articles published since 2019 Epidemiology, screening and diagnosis, surgical management, radiation management and systemic management of lung cancer in different countries around the globe
Controversies in Thoracic Oncology (Pro/Con Series)	<ul style="list-style-type: none"> 26 articles published since 2021 “Pro and Con” opinion pieces from experts dealing with topics that are open to debate
Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors	<ul style="list-style-type: none"> From the IASLC Staging and Prognostic Factors Committee Newly published articles in this series are being added to the IASLC Staging Articles Collection
NEW INITIATIVES	DESCRIPTIONS
Graphical Abstracts	<ul style="list-style-type: none"> Provide visual summary of key contents from the study to enhance readers' experience Available for Original Article and Brief Reports only
e-Publication	<ul style="list-style-type: none"> Online only publication starting in January 2024

Most cited articles published in 2023

CITATIONS IN 2023	ARTICLE TITLE	AUTHORS
45	Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study	Girard N., Bar J., Garrido P., Garassino M.C., McDonald F., et al.
19	First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations	Paz-Ares L.G., Ciuleanu T.-E., Cobo M., Bennouna J., Schenker M., et al.
19	SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection	Wang Q., Gumus Z.H., Colarossi C., Memeo L., Wang X., Kong C.Y., Boffetta P.
16	UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-Line Setting (UNICORN)	Bar J., Peled N., Schokrpur S., Wolner M., Rotem O., et al.
14	Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial	Zhou C., Huang D., Fan Y., Yu X., Liu Y., et al.
14	MET Alterations in NSCLC—Current Perspectives and Future Challenges	Remon J., Hendriks L.E.L., Mountzios G., et al.
12	Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers	Choudhury N.J., Marra A., Sui J.S.Y., Flynn J., Yang S.-R., Falcon C.J., et al.
12	Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial	Craddock M., Nestle U., Koenig J., Schimek-Jasch T., et al.
11	NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC	de Castro G., Rizvi N.A., Schmid P., Syrigos K., Martin C., et al.
11	Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival	McWilliam A., Abravan A., Banfill K., Faivre-Finn C., van Herk M.
11	Stage Shift Improves Lung Cancer Survival: Real-World Evidence	Yang C.-Y., Lin Y.-T., Lin L.-J., Chang Y.-H., et al.
9	Selective Mediastinal Lymph Node Dissection Strategy for Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial	Zhang Y., Deng C., Zheng Q., Qian B., Ma J., et al.
9	Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis	Triphuridat N., Zhang S.S., Nagasaka M., Gao Y., et al.
9	Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC	Ernst S.M., Mankor J.M., van Riet J., von der Thusen J.H., et al.
9	Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia	Mitsudomi T., Tan D., Yang J.C.-H., Ahn M.-J., Batra U., et al.
9	Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies	Dagogo-Jack I., Abbattista A., Murphy J.F., Krulewicz S., et al.

JTO Clinical and Research Reports Shaping Global Access to Lung Cancer Studies


The IASLC's commitment to accessible knowledge is embodied by *JTO Clinical and Research Reports (JTO CRR)*, our open-access journal. This platform ensures immediate and enduring free access to high-quality lung cancer studies for everyone. As the companion journal to JTO, JTO CRR finds its niche within the IASLC by providing a dedicated space for research with a clinical focus, including case reports, phase 1 and 2 trials, impactful retrospective studies and database analyses.

VISIBILITY AND RECOGNITION: A YEAR OF ACHIEVEMENTS

In 2021, JTO CRR achieved indexation in PubMed Central, the Directory of Open Access Journals, and Scopus. By the end of 2023, the journal reached another milestone by gaining acceptance into Clarivate's Emerging Source Citation Index (ESCI), a part of the Web of Science core collections. This accomplishment positions JTO CRR on the path to obtaining its first impact factor, slated for release in June 2024.

A GROWING COMMUNITY

The success and continuous growth of JTO CRR are indebted to our dedicated readers, authors, and reviewers. This open-access journal has become a vital resource, extending the IASLC's influence worldwide, offering unparalleled access to the thoracic oncology community.



Emily Stone, MBBS, PhD, FRACP
Editor-in-Chief, JTO CRR


Most cited articles published in 2023

CITATIONS IN 2023	ARTICLE TITLE	AUTHORS
12	Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC	Garassino M.C., Gadgeel S., Novello S., Halmos B., Felip E., Speranza G., Hui R., Garon E.B., Horinouchi H., et al.
7	Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC	Hofman V., Heeke S., Bontoux C., Chalabreysse L., Barritault M., Bringuiet P.P., Fenouil T., Benzerdjeb N., et al.
7	Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry	Mountzios G., Planchard D., Metro G., Tsiouda D., Prelaj A., Lampaki S., Shalata W., Riudavets M., Christopoulos P., et al.
6	Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC	Gibson A.J.W., Pabani A., Dean M.L., Martos G., Cheung W.Y., Navani V.
4	Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report	Diep R., MacDonald M., Cooper R., Grzegorzczak A., Rakocevic R., Chang C.-F., Uy A., Cowgill N., Nieva J.J.
4	The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations	Kagawa Y., Hayashida T., Liu J., Mori S., Izumi H., Kumagai S., Udagawa H., Hattori N., Goto K., Kobayashi S.S.
3	Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions	Sandoval M.L., Sim A.J., Bryant J.M., Bhandari M., et al.
3	Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors	Unal S., Winkelman J.A., Heineman D.J., Bahce I., van Dorp M., et al.
3	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)	Miura S., Nishio M., Akamatsu H., Goto Y., Hayashi H., et al.
3	Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study	Ji J., Aredo J.V., Piper-Vallillo A., Huppert L., Rotow J.K., Husain H., Stewart S., Cobb R., et al.



IASLC Lung Cancer News

IASLC Lung Cancer News (ILCN) is the IASLC's official news source for thoracic oncology specialists throughout the world. With its international audience, ILCN offers timely and relevant lung cancer news that spans specialties and interests as well as geography. ILCN's analysis helps clinicians understand the implications of the latest research in medical, radiologic, and surgical oncology, as well as pathology, nursing and allied health, patient advocacy, and more.



THE VOLUNTEERS WHO MAKE ILCN POSSIBLE



EDITOR
Corey J. Langer, MD, FACP



ASSOCIATE EDITOR
Mary Jo Fidler, MD



ASSOCIATE EDITOR
Witold K. Rzyman, MD



ASSOCIATE EDITOR
Suresh Senan, MD

Editorial Group Members

Fabrice Barlesi, MD, PhD
 Ross Camidge, MD, PhD
 Edgardo S. Santos Castillero, MD, FACP
 Jose Francisco Corona Cruz, MD, FACP
 Marianne Davies, DNP, ACNP, AOCNP
 Anne-Marie C. Dingemans, MD, PhD
 Ivy Elkins, MBA

Shirish Gadgeel, MDG
 Bruno Hochegger, MD, PhD
 Deepali Jain, MD
 Angus Pratt, MBA
 Karen Reckamp, MD
 Christian Rolfo, MD, PhD, MBA
 Ricardo Sales dos Santos, MD, PhD

Joan H. Schiller, MD, FACP
 Brendon Stiles, MD
 Aaron Tan, MD, PhD, FRACP
 Ricardo Terra, MD, PhD, MPH
 Murry Wynes, PhD
 Caicun Zhou, MD, PhD

Managing Editor

Erin Jungmeyer, TriStar Event Media

ILCN Staff Liaison

Jan Mazotti, Associate Director of Communications & Marketing, IASLC

Learn more about ILCN's editorial group [here](#).



THE IASLC LUNG CANCER NEWS BY THE NUMBERS

In 2023, ILCN received **164,690** unique page views by **92,295** users around the world. The top 10 countries represented by ILCN's **90,000+** readers are:

1

UNITED STATES

2

UNITED KINGDOM

3

INDIA

4

CANADA

5

CHINA

6

JAPAN

7

SINGAPORE

8

AUSTRALIA

9



SOUTH KOREA

10


ITALY

Top 10 Articles and Pages in 2023

1. **Comments on 8th Edition of TNM Classification of Lung Cancer**
2. **A Holistic Approach to Patient Care**
3. **Lung Cancer in Never-Smokers: An Epidemiologic Perspective**
4. **MARS2: Decortication Plus Chemotherapy Associated with Worse Outcomes for Resectable Mesothelioma**
5. **Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture**
6. **IASLC Staging Project Finalizing Recommendations for 9th Edition of TNM Classification System**
7. **CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients with Lung Cancer**
8. **WCLC 23 Attendee Map & Photo Gallery**
9. **Real-World Data from Taiwan Shows Stage Shift has Improved Lung Cancer Survival Rates**
10. **Proton Beam Therapy Versus Photon Beam Therapy: The Debate Continues**



LUNG CANCER CONSIDERED



with **Dr. Stephen Liu** and **Dr. Narjust Florez**
an IASLC Podcast

Bleeding Conversations, Expanding Reach

Podcast Excellence in 2023: A Year of Achievements

Tune in to Lung Cancer Considered, the official IASLC podcast, for engaging conversations with internationally recognized researchers, healthcare professionals, patients, and advocates influencing the landscape of thoracic cancers.

In 2023, Lung Cancer Considered experienced an unprecedented surge in listenership, surpassing 227,000 dedicated listeners globally. This remarkable achievement was acknowledged with the prestigious W3 Gold Award for creative excellence, highlighting the podcast's impactful contribution to the field.

Diverse Content, Global Impact: 59 Episodes in Multiple Languages

Throughout the year, Lung Cancer Considered released a total of 59 episodes, delving into various facets of thoracic cancer care. What sets the podcast apart is its commitment to inclusivity, with 12 episodes available in multiple languages, including Dutch, French, Greek, Hindi, Hungarian, Italian, Japanese, Korean, Mandarin, Polish, and Portuguese. This multilingual approach ensures that valuable insights reach a broader and more diverse audience, fostering a truly global conversation.

Expanding Platforms: Now on Spotify

In an effort to make these crucial discussions even more accessible, Lung Cancer Considered expanded its reach by joining the Spotify platform. Beyond its existing presence on Apple Podcasts and SoundCloud, this expansion ensures that listeners can engage with the podcast conveniently on the platform of their choice.

Join the Conversation: Wherever You Are

Lung Cancer Considered invites you to listen and join the conversation. Whether you are a healthcare professional, researcher, patient, or advocate, the podcast provides a platform to explore the latest advancements, personal stories, and insights that shape the future of thoracic cancer care. Subscribe, listen, and be part of the dialogue that matters.

In 2023, Lung Cancer considered was funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda.

Listen here
and join the
conversation.




Dr. Narjust Florez, one of the co-hosts of Lung Cancer Considered, reflects on the podcast's achievements throughout 2023.



Lung Cancer Considered by the Numbers

LISTENS BY YEAR



227,000
ALL-TIME LISTENS

TOP COUNTRIES



TOP 10
PODCASTS IN 2023

Title of Podcast	Total Listens
ASCO 2023 Highlights	2,476
Evolving Role of Liquid Biopsy for Lung Cancer	2,009
Updated ADAURA - Future of Targeted Therapy in Lung Cancer	1,788
Virtual Tumor Board: Resectable Stage III NSCLC	1,727
FDA Approval of Adjuvant Pembrolizumab for NSCLC	1,667
EGFR Mutant NSCLC Post Osimertinib	1,641
EGFR Exon 20 Insertions in NSCLC	1,635
SCLC Transformation in EGFR NSCLC	1,630
TTLC 2023 Meeting Recap	1,569
Meeting the New JTO CRR Editor-in-Chief	1,507

Committees

2023-2024

Volunteers are the heart of the IASLC, with each member bringing their unique skills and talents to actively shape the organization's initiatives. Their dedicated contributions extend across a spectrum of vital tasks, including providing input on the new IASLC Strategic Plan, crafting educational content, playing a vital role in orchestrating IASLC meetings, creating scientific publications, and more.

Each committee operates under the guidance of the IASLC Board of Directors and is led by a chair (or co-chairs), with additional support from a board liaison, the past chair, the deputy chair and a staff liaison. Currently navigating through their 2023-2025 term, committee members were thoughtfully selected to ensure a blend of relevant expertise and diversity, in terms of regional representation, specialties and gender. This strategic approach ensures a well-rounded and inclusive foundation for the impactful career-level work carried out by each committee.



Advanced Radiation Technology (ART) Committee

The ART Committee spearheads advancements in education, clinical management, and research pertaining to radiotherapy for thoracic malignancies. Committee members have orchestrated numerous educational initiatives, including webinars and podcasts. Noteworthy among this year's webinars are “**Current Approaches and Future Directions in Radiotherapy for Small Cell Lung Cancer**” and a collaboration with the IASLC Education/CME Committee on “**2023 Radiation Oncology Updates**,” shedding light on impactful studies and other groundbreaking radiation updates.

In a spirit of collaboration, the committee has worked closely with other radiation oncology societies to develop guidelines and content. One notable outcome of this collaboration was the joint IASLC/ASTRO session held in October 2023, titled “Modern Principles in the Diagnosis and Management of Radiation Pneumonitis.” **Dr. Alexander Louie** from Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, serves as the dedicated committee chair, steering the committee's efforts toward the forefront of advancements in thoracic radiotherapy.

Career Development & Fellowship Committee

In 2023, the Career Development & Fellowship Committee was disbanded, and two new entities were created in its place: the Career Development Committee and the Grant Review Panel.

This Committee is charged with fostering and advancing careers across the professional continuum by providing diverse opportunities in research, education, clinical care, and leadership in the field of thoracic malignancies worldwide. **Dr. Tindara Franchina** from the University of Messina in Italy is the incoming committee chair. The Career Development Committee is considered a new IASLC Committee, and as such, that committee will not begin its work until early 2024.

The Grant Review panel will focus on providing support for the next generation of lung specialists by awarding research grants. The committee reviews and scores grant applications and selects **grant recipients**. In 2023, the review panel reviewed 51 grant applications and selected nine recipients, awarding \$750,000 in grants.



Communications Committee

The Communications Committee is dedicated to advancing the recognition and credibility of IASLC while fostering public understanding of lung and thoracic cancer complexities. This encompasses designing strategic campaigns to enhance the IASLC brand, curating relevant articles from the *Journal of Thoracic Oncology* for media amplification, and utilizing diverse platforms such as press releases, **Lung Cancer Considered** podcasts, and *ILCN* articles to share precise information globally.

Furthermore, the committee convened a **workshop during WCLC 2023**, providing attendees with invaluable insights from prominent figures in lung cancer. Participants gained essential skills such as advocating for health equity in scientific communications, deciphering data in presentations, simplifying statistical and methodological aspects in scientific discourse, effective manuscript review techniques, navigating the nuances of scientific communications with the press, and leveraging social media for scientific outreach. **Dr. Jarushka Naidoo**, Full Professor of Medical Oncology and Consultant Medical Oncologist at Beaumont RCSI Cancer Centre in Dublin, Ireland, and Adjunct Faculty at Johns Hopkins University, leads the committee as chair.



Continuing Medical Education Committee

The International Association for the Study of Lung Cancer (IASLC) is accredited by the ACCME to provide continuing medical education for physicians. The CME Committee ensures all accredited activities meet the ACCME accreditation requirements, including the ACCME Standards for Integrity and Independence in Accredited Continuing EducationSM. The CME Committee also ensures IASLC CME activities meet the requirements of the American Medical Association Physician's Recognition Award (AMA PRA). The 2023 CME Co-Chairs are **Apar Kishor Ganti** and **Nick Pavlakis**. Dr. Nick Pavlakis of the Royal North Shore Hospital in Australia serves as chair of the CME subcommittee.

Education Committee

The Education Committee realizes IASLC's mission to provide education and information about lung cancer and other thoracic malignancies to IASLC members, the medical community at large, and the public. The committee works to identify educational needs and practice gaps, develop learning objectives, facilitate accredited and non-accredited educational programs, and evaluate the effectiveness of IASLC educational activities. The 2023 chairs were Christian Rolfo, Chair and Pranshu Mohindra, Deputy Chair. Dr. Pranshu Mohindra of Case Western Reserve University in Ohio, USA, will serve as the 2024 committee chair, with Hidehito Horinouchi of the National Cancer Center in Tokyo, Japan, serving as Deputy Chair.

Membership Committee

The Membership Committee sets strategy and implements tactics to increase and retain association membership across specialties and regions while focusing on sharing the message of the IASLC and ensuring the benefits it offers are of great value for thoracic oncology professionals. One of the committee's goals is to foster relationships with new members from around the globe. In 2023, as part of its responsibilities, the Membership Committee assisted IASLC staff with the analysis of the 2022 Member Survey, which provided valuable insight into our members and their needs. Along with their regular duties of reviewing and recommending membership status requirements and benefits for all IASLC members, committee members also helped to plan the Committee Corner at WCLC 2023. **Dr. Sudish Murthy** of Cleveland Clinic in Cleveland, Ohio, USA, is the committee chair.



Mesothelioma Committee

The Mesothelioma Committee seeks to accelerate the pace of research and work across geographies to develop strategic research goals and to bring the disease to the forefront of research. This year, the committee orchestrated a collaborative workshop during WCLC 2023 titled, “Modern Pathology Guided Treatment of Mesothelioma: What’s Now and What’s Next.” This workshop covered treatment options for mesothelioma patients based on their pathological and molecular profiles. A key highlight of the workshop was an engaging discussion led by specialists who analyzed selected cases, providing the audience with valuable insights into current and upcoming treatment options.

The Mesothelioma Committee has been at the forefront of several research updates in the field in recent years, reflecting their commitment to advancing knowledge and understanding. **Dr. Aaron Mansfield**, from Mayo Clinic in Rochester, Minnesota, USA, serves as the esteemed chair of the committee, guiding its efforts to propel mesothelioma research into new frontiers.

Nursing & Allied Health Professionals Committee

The Nursing & Allied Health Professionals Committee (NAHP) is composed of multidisciplinary clinicians and researchers, each with a unique perspective, and is committed to advancing the education of both practitioners and patients in thoracic oncology. The committee’s goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship, and end-of-life. In 2023, the NAHP Committee collaborated with ITONF at WCLC 2023 to host a workshop titled: **“Thoracic Oncology Care: Do We Know WHAT To Do And How Do We KNOW?”** seeking to highlight the knowledge and expertise thoracic oncology nurses and AHPs bring to the multidisciplinary team in the care and treatment of patients with lung cancer and mesothelioma. The workshop covered the latest treatment options, global issues in cancer care and nursing and AHP-driven research initiatives. **Michelle Turner** of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Maryland, USA, is the committee chair.



Pathology Committee

The Pathology Committee helps fulfill core aspects of IASLC’s mission, including producing publications, such as **IASLC Atlas of Molecular Testing for Targeted Therapies in Lung Cancer**, offering guidance for the organization’s annual slate of meetings, and helping to establish the IASLC as an international leader in the clinical and scientific aspects of lung cancer pathology. This committee represents the IASLC in guideline development for the **World Health Organization’s (WHO) “Classification of Lung Tumors”** and the **CAP-IASLC-AMP guidelines**, which are currently being updated and will be published in 2024. During 2023, the committee authored and published three pioneering JTO articles:


- › **International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy**
- › **MA12.07 Defining Morphologic Features of Invasion in Pulmonarynon-Mucinousadenocarcinoma with Lepidic Growth**
- › **Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment**

This team is also instrumental in the IASLC’s **Pathologic Response Initiatives**. **Dr. Wendy Cooper** of the Royal Prince Alfred Hospital in Australia chaired the Pathology Committee for the 2021-2023 term.

Patient Advocates Committee

The Patient Advocates Committee (PA) is a dedicated group of individuals committed to ensuring the IASLC effectively addresses the informational needs of the public, advocates, and patients living with lung and other thoracic cancers. The PA Committee works to address the direct impact research has on its beneficiaries—patients with lung cancer—and focuses on how they can support continued research to improve treatment options and availability. By actively advocating for patient perspectives, the PA Committee informs decision-making processes by the IASLC Board and other committees to ensure the association's activities align with the needs of patients with lung cancer and their caregivers/partners.

The committee dedicated efforts to implement the IASLC Language Guide in 2023. They also worked to explore collaboration opportunities to create patient guides and resources, including patient-friendly research summaries. Members were responsible for overseeing the **Education Awards** and **Cancer Care Team Awards** for 2023. The committee continues to collaborate with other IASLC committees, providing input and a patient advocacy perspective to other focus areas. **Shani Shilo**, DMD, PhD, Israeli Lung Cancer Foundation, chairs the Patient Advocates Committee.



Screening & Early Detection Committee

The IASLC Screening and Early Detection Committee is a multi-disciplinary group dedicated to advancing screening and early detection programs through education and research across the globe. Committee members include leaders from radiology, thoracic surgery, pulmonary medicine, medical oncology, nursing, basic science, and advocacy organizations from North America, Europe, Asia, and South America. **Dr. Stephen Lam** of the BC Cancer Center in Canada was the chair of the Screening and Early Detection Committee for the 2021-2023 term.



2023 Committee Publications:

Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee

Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

Perspective on Management of Low-Dose Computed Tomography Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening. From the International Association for the Study of Lung Cancer Early Detection and Screening Committee

Tobacco Control & Smoking Cessation Committee (TCSC)

The Tobacco Control and Smoking Cessation Committee’s mission is to contribute to global efforts to prevent lung cancer and improve the clinical outcomes of patients with lung cancers through tobacco control and smoking cessation. The committee ensures IASLC addresses the needs of practitioners seeking to help their patients cease tobacco use as well as recommends actions to contribute to international, national, and local efforts in tobacco control through research, initiatives, and interventions.

In 2023, the committee updated their mission statement and terms of reference, disseminated the “**IASLC Position Statement on Tobacco Cessation After a Cancer Diagnosis**” to numerous global organizations, authored the “**IASLC Position Statement on the Documentation of Tobacco Use in Clinical Trials**,” which was highlighted by a special article in **Lancet Oncology**, ensured that Tobacco Moments were embedded into IASLC conferences, provided committee members for the **IASLC WCLC 2023 program committee** to create tobacco control and smoking cessation content for the World Conference, awarded Xinan Wang, PhD, and Zhuangzhuang Liu, MD, the Early Career in Tobacco Control and Smoking Cessation and Developing Nations in Tobacco Control and Smoking Cessation awards, respectively, at WCLC 2023, and wrote and sent a **letter to the New Zealand Prime Minister** asking their legislators not to rescind the anti-tobacco legislation “Aotearoa/New Zealand Tobacco Action Plan,” which is regarded as a model for the world to prevent many lung cancer cases and deaths that would otherwise occur as a result of smoking. **William (Bill) K. Evans, MD, FRCP**, recipient of the **Joseph W. Cullen Prevention/Early Detection Award** at WCLC 2023, of McMaster University in Canada was the chair of the committee and **Joelle Fathi, DNP, RN, ARNP, FAAN** of the GO2 Foundation for Lung Cancer, was the deputy chair.



New Committees

The IASLC is delighted to share the exciting news of the inauguration of six new committees: Rare Tumors, Basic and Translational Science, Global Policy and Partnerships, Multidisciplinary Clinical Science, Global Multidisciplinary Practice Standards, and the Career Development Committee. Anticipating their official launch in the first quarter of 2024 as one of the first objectives of the new IASLC strategic plan, we are thrilled to have received an unprecedented number of applications from exceptionally qualified candidates worldwide, emphasizing the global enthusiasm and commitment to advancing our mission.



Elevating Patient Advocacy in the Fight Against Lung Cancer

PHENOMENAL GROWTH IN LUNG CANCER ADVANCEMENTS

Over the past decade, the landscape of lung cancer detection, patient care, and treatment options has witnessed unprecedented growth. Recognizing the indispensable role played by patients, caregivers, and advocates in shaping the lung cancer community, the IASLC is dedicated to fostering inclusivity and accelerating the pace of knowledge-sharing and advancements in care.

Empowering Patient Advocates: A Commitment to Inclusivity

The IASLC is committed to offering patient advocates a seat at the table, providing opportunities to:

- › **Participate in Conferences:** Access to key conferences where advocates can stay abreast of the latest developments in lung cancer research and care.
- › **Build Relationships:** Forge meaningful connections with researchers and care providers to enhance collaboration.
- › **Engagement & Empowerment:** Sit side-by-side with researchers and care team members, contributing their unique insights to the collective understanding of lung cancer and helping research generate meaningful outcomes for patients and their families.
- › **Share Experiences:** Facilitate the sharing of personal perspectives and experiences, enriching the dialogue around lung cancer.



IASLC Supportive Training for Advocates on Research & Science

IASLC Supportive Training for Advocates on Research & Science (STARS)

The Patient Research Advocates (PRAs) within the STARS program are instrumental individuals with a personal connection to cancer who are passionate about translating research into tangible outcomes for patients and their families. Lung cancer patient research advocates within this program bring the collective patient perspective to the forefront, ensuring research aligns with patients' most pressing needs.

Expanding Opportunities in 2023: Three Unique STARS Programs

- 1. STARS PRA Program:** Tailored for advocates exploring PRA opportunities, this all-virtual training program includes webinars, education sessions, online learning, and networking opportunities.
- 2. STARS Scholar Program:** Specifically designed for experienced patient research advocates, this program offered in-person activities at WCLC 2023. It includes a full-day workshop, educational opportunities, and networking sessions.
- 3. STARS Alumni Program:** Geared toward sustaining PRA education and networking, this program is open to all previous STARS participants, fostering an ongoing community of learning and collaboration.

The IASLC is proud to champion patient advocacy, recognizing it as an integral force in propelling lung cancer research, care, and outcomes. As we reflect on the strides made in 2023, we look forward to furthering our commitment to inclusivity and collaboration in the years to come.



Patient Advocate Education Awards

The IASLC Patient Advocate Educational Awards serve as a gateway for patients/survivors, caregivers, and advocates to participate in the IASLC's premier global event—the IASLC World Conference on Lung Cancer (WCLC). In 2023, IASLC proudly granted six Education Awards to patient advocates from diverse corners of the globe.

For more information on the Patient Advocate Education Awards, please visit www.iaslc.org/patient-advocacy/patient-advocate-education-awards.



2023 Patient Advocate Education Award Winners

Graham Hall, Australia
 Isaac Joseph, Nigeria
 Miryana Perez Vela Nieto, Mexico
 Aditya Manna, India
 Annabelle Gurwitch, USA
 Yvonne Diaz, UK

IASLC Cancer Care Team Award

The IASLC Cancer Care Team Award is a prestigious award honoring and recognizing multidisciplinary teams who provide exceptional care to patients. Patients with lung cancer and/or their loved ones from all across the world nominate their cancer care teams. The IASLC is proud to honor the following winning teams of the 2023 IASLC Cancer Care Team Award:

Recognizing Outstanding Patient Care in the Field of Thoracic Malignancies.

CANCER CARE TEAM AWARD

**North American Recipient: Massachusetts General Hospital, Boston, MA
 New York Oncology & Hematology, Albany, New York**

Latin American Recipient: Oncosalud - AUNA, Lima, Peru

**Asia/ROW Recipient: Yonsei Cancer Center, Yonsei University in Seoul
 Republic of Korea (South Korea)**

Europe Recipient: Medical University of Gdańsk, Gdańsk, Poland

Thank you to our Sponsors

GOLD SPONSORS

Genentech
 A Member of the Roche Group

GILEAD | Oncology

SILVER SPONSORS



Bristol Myers Squibb



NOVARTIS

sanofi





IASLC Diversity, Equity, & Inclusion Initiative

Fostering Global Collaboration and Impact

In 2023, the IASLC board of directors assembled a diverse taskforce of members who began working together to develop a Diversity Equity and Inclusion (DEI) action plan that aligns with the IASLC mission, as well as educational and research initiatives that address DEI needs. The taskforce developed the following statement to summarize IASLC's beliefs regarding DEI.

IASLC's DEI Statement:

A Commitment to Global Collaboration

As a professional association with a global membership and commitment to diversity, equity, and inclusion (DEI), the IASLC plays an important role in promoting global DEI. The IASLC recognizes, supports, and celebrates the unique contributions of people from different scientific disciplines, personal identities, regions, and cultures, and welcomes the opportunity to expand a global inclusive and collaborative community of researchers, clinicians, patients, advocates, and other stakeholders. Through cross-cultural understanding, communication, and collaboration the IASLC seeks to improve the everyday life of people affected by thoracic cancers worldwide.

Partnership with The Equity Project: **Driving Comprehensive Equity Assessment and A Blueprint for Progress**

In addition, the IASLC has contracted with The Equity Project to support the DEI Taskforce and conduct a comprehensive equity assessment that will help identify the strengths that already exist within the IASLC, as well as key areas for opportunity and growth. Results from this assessment will inform the development of a DEI strategic plan with benchmarks, action items, and systems of accountability for IASLC. IASLC's DEI strategic plan will include strategies that target internal goals to address key stakeholder feedback, as well as new DEI initiatives within the organization.

Looking Ahead:

A Shared Commitment to Progress

As the IASLC moves forward, the DEI initiatives underscore a shared commitment to progress and inclusivity. The organization is poised to leverage its global reach and influence to drive positive change in the field of thoracic cancers, enriching the lives of patients, caregivers, researchers, clinicians, and advocates across the world. The IASLC remains steadfast in its dedication to promoting diversity, equity, and inclusion as integral components of its mission.



IASLC PARTNERS FOR THORACIC CANCER CARE



2023 Progress Report

In response to insightful feedback gathered during engagements with Corporate Partners in 2022, IASLC introduced the groundbreaking IASLC Partners for Thoracic Cancer Care initiative. This collaborative effort seamlessly integrates the expertise of IASLC member experts with industry representatives, fostering collective solutions to major challenges in the field of lung cancer and thoracic malignancies.

Strategic Focus on Biomarker Testing: Elevating Diagnostic Precision

The initiative's inaugural phase is strategically centered on biomarker testing, recognizing its critical role in ensuring accurate diagnoses of lung cancer. Through collaborative projects, IASLC Partners aim to advance biomarker testing methodologies, ultimately contributing to enhanced diagnostic precision and improved patient outcomes.

Expanding Horizons in 2024: Addressing Critical Issues


Looking ahead to 2024, the IASLC Partners initiative is set to broaden its scope. Plans include the addition of new partners and the formation of specialized working groups dedicated to addressing pressing topics such as access to clinical trials, early detection and screening, and disparities in care. This forward-looking approach ensures the initiative's adaptability to emerging challenges.

Diverse Leadership Steering Progress

The initiative is spearheaded by a distinguished and globally representative group of co-chairs, each bringing unique perspectives and expertise to the table. The current co-chairs are:

- ▶ Federico Cappuzzo, MD, National Cancer Institute Regina Elena (Italy)
- ▶ Byoung Chul Cho, MD, PhD, Yonsei Cancer Center (Republic of Korea)
- ▶ Eric Churchill, PhD, Takeda Oncology (USA)
- ▶ Abdelali Majdi, MD, Bayer (France)
- ▶ Sukhmani Kaur Padda, MD, Fox Chase Cancer Center/Temple Health (USA)
- ▶ Navneet Singh, MD, FRCP, Postgraduate Institute of Medical Education and Research (India)

Their leadership ensures a comprehensive and inclusive approach to the initiative's objectives.



Distinguished Corporate Participation in 2023

The success of the IASLC Partners initiative is further accentuated by the active involvement of leading corporations. Their engagement signifies a shared commitment to advancing thoracic cancer care on a global scale. The 2023 participants include:



The IASLC Partners for Thoracic Cancer Care initiative stands as a testament to collaborative efforts shaping the future of thoracic cancer care.

Corporate Relations

In 2023, IASLC transformed its approach to corporate fundraising through a relationship-driven program. Bolstered by new staff, the initiative included regular monthly calls with partners and immersive meetings at various conferences. The team not only met, but exceeded, fundraising goals by fortifying existing partnerships, diversifying the sponsorship portfolio, and introducing innovative opportunities that mutually benefit both the IASLC and its corporate collaborators.

Beyond Meetings:

Specialized Partnerships for Holistic Support

Our commitment to corporate partners goes beyond traditional meetings and events. IASLC offered specialized partnerships tailored to support the development of critical resources, programs, scientific projects, and more. This strategic collaboration approach ensures a comprehensive and lasting impact on the initiatives that drive our mission forward.

Gratitude to Top Sponsors of 2023

We extend heartfelt appreciation to the top sponsors of 2023 for their unwavering support and commitment. It is through these valued partnerships that we continue to advance our mission in the study and treatment of lung cancer, making a meaningful impact on the global thoracic cancer community.



To explore all the opportunities to engage with the IASLC, please contact us at corporaterelations@iaslc.org.

IASLC FOUNDATION



INSPIRING HOPE THROUGH RESEARCH

Despite advances in research and early detection that are creating better outcomes and hope for lung cancer patients and their families, lung cancer claims more lives each year than breast, colon, and prostate cancers combined. Yet lung cancer receives disproportionately less government research funding per cancer death than other types of cancer. This makes the need for private support of lung cancer research critical.

The IASLC Foundation exists to provide opportunities for innovative research. Donations from patients, caregivers and other individuals, as well as from our organizational and corporate partners, directly fund our Research Grants Program—a global initiative to provide researchers in all stages of their careers with vital funding opportunities, fostering both tomorrow’s thoracic cancer visionaries and achieving milestones in patient care. Together, we will accelerate the pace of research and inspire hope for those affected by lung cancer worldwide.

IASLC Foundation Advisory Board



David Carbone
Chair, USA



David Gandara
Deputy Chair, USA



Heather Wakelee
IASLC Past President, USA



Lauren Fisher
Advisory Board Member, USA



Debbie Johnson
Advisory Board Member, USA

2023 Research Grant Recipients



In 2023, the IASLC Foundation awarded nine research grants totaling \$750,000. This year’s grant recipients represent another diverse group of researchers from around the world. IASLC Foundation Research Grants are made possible by donations from individual donors, foundation partners and pharmaceutical companies and foundations.

2023 YOUNG INVESTIGATOR GRANT RECIPIENTS: For investigators who are ready to begin independent research studies, the IASLC Foundation offers numerous grants on an annual cycle, dependent on the geographic region of the applicant. These one-year grants are for \$50,000 in research funding.



Amy Cummings
University of California, Los Angeles, USA
Project Title: Immunogenic Peptide Priming of Dendritic Cells for Enhanced Immunotherapy Approaches in Resectable Non-Small Cell Lung Cancer (NSCLC)



Adrien Constantini
Université Paris Saclay, France
Project Title: MHC Class-I Antigen Processing and Presentation Deficiency in Non-Small Cell Lung Cancer

2023 FELLOWSHIP GRANT RECIPIENTS: Exclusive to fellows, these grants provide \$50,000 for a one-year research project. Opportunities are numerous and based on the geographic region of the applicant.



Regina Hoo
National Cancer Centre Singapore, Singapore
Project Title: A Spatially Resolved Roadmap for Tracking Adaptation and Response to Targeted Therapies in EGFR-driven NSCLC
Watch the Video here



Griselda Awanis
Cancer Research UK Manchester Institute, United Kingdom
Project Title: Suppression of Vasculogenic Mimicry, via FAK Inhibition, as a New Therapeutic Strategy for SCLC Treatment



Luis Prieto
Mayo Clinic, Rochester, Minnesota, USA
Project Title: Mechanistically Evaluating Why Aging Predisposes to Cancer



2023 LCFA/BMS/ILCF YOUNG INVESTIGATOR RESEARCH GRANT RECIPIENTS: Disparities In Clinical Oncology Research Grant LCFA/BMS/ILCF

Young Investigator Research Grant in Translational Immuno-oncology: To support research in translational immuno-oncology undertaken by early-career investigators that aim to improve the care and treatment of individuals with lung cancers. Up to two grants may be given in this funding cycle, and each will be \$100,000 per year for up to two years.



Aparna Sharma
All India Institute of Medical
Sciences, India
Project Title: Genomic
Characterization of Young Onset
Lung Adenocarcinoma in India
(YOLA-I study)

2023 Foundation Partner



2023 Industry Partners



Jazz Pharmaceuticals®



MERCK

novocure®

2023 Individual Donations

The IASLC Foundation received \$112,581.37 in individual donations in 2023—an increase of 44% over the previous year. Donations at WCLC exceeded the generous \$15,000 matching gift pledge by Dr. David Carbone and Dr. David Gandara.

We thank everyone who donated to support lung cancer research in 2023.

2023 IASLC Foundation LLC Donors

TOP DONORS

Adi Gazdar Estate
Executor Sheldon Asnien
Anonymous Donor
David Gandara
David Carbone

1,000 - \$2,999

David Harpole
Greg Galanos
Fred Hirsch
Heather Wakelee
Jason Porter
Lauren Fisher
Lecia Sequist
Roy Herbst

\$500 - \$999

Alex J Nadler
Andrea Bezjak
Bredon Stiles
David Shames
Etsuo Fujita
HWN Energy Ltd.
Karen Kelly
Matthew Yeingst

Michelle Brockman
Natasha Leighl
Robert Pirker
Stephen Burger

\$100 - \$499

Aki Kobayashi
Amy O'Donnell
Andrea Borondy Kitts
Aneez Ahmed Dokeu
Angela Takano
Anita Archwamety
Anjali Saqi
Anonymous Donor
Anonymous Donor
Barbara Hefner
Benjamin Solomon
Bo-Tsang Huang
Bruce Dunbar
Caicun Zhou
Calvin Ng
Carolyn Presley
Cheryl Ho
Christine Hann
Corey Langer
Darren Casonhua
David Ball
David Gierada
Debora Bruno
Diane Legg
Douglas Arenberg
Ebenezer Kio
Edwina Duhig

Elizabeth Hastings
Emily Stone
Eric Bernicker
Estelamari Rodriguez
Eva Ehrnrooth
Feng-Ming Spring Kong
Ferdinando Cerciello
Gerard Hanna
Gregory Moyer
Guoping Cai
Harriet Kaplan Suvall
Harvey Pass
Helmut Prosch
Hong Kwan Kim
Hong Liu
Hossein Borghaei
J. Jean Cui
Jacquelyn Nixon
James Chih-Hsin Yang
Janice Neff
Janny Rijlaarsdam
Jay Van Duffelen
Jin Soo Lee
John Timmins
John M. Hoehn
Joyce Barnathan and Steven Strasser

Kathy Price
Keith Kerr
Keunchil Park
Kim Cooper
Louis Geeraerts
Luka Brcic
Makenzi Evangelist
Mari Mino-Kenudson
Maria Pietanza
Masahiro Tsuboi
Matthew Gubens
Matthijs Oudkerk
Meng Welliver
Michael Boyer
Mitchell Machtay
Myung-Ju Ahn
Nick Pavlakis
Nico van Zandwijk
Nisus Corporation
Pan Zheng
Patricia Benjamin
Paul Van Schil
Peter Illei
Rafael Meza
Regan Memmott
Ricardo Salgado
Ross Soo

Sanja Dacic
Se-Hoon Lee
Sergio Santillana
Shengxiang Ren
Sherry Baskerville-Bridges
Stephen Lam
Steven Keller
Sukhmani Padda
Sunhee Malinowski
Suresh Ramalingam
Susan Anderson
Susan Schwartz
Taofeek Owonikoko
Teh-Ying Chou
Tetsuya Mitsudomi
Ticiania Leal
Umberto Malapelle
William Travis
William Evans
William Walsh
Xiao Li
Yang Liu
Yasushi Yatabe
Yi-Long Wu
Yoon-La Choi
Young Tae Kim

IASLC Foundation, LLC is wholly-owned as a disregarded entity by the International Association for the Study of Lung Cancer (IASLC), a nonprofit corporation exempt from taxation under Section 501(c)(3) of the Internal Revenue Code (EIN 200499338). Contributions to IASLC Foundation, LLC are treated as charitable contributions to a branch or division of IASLC.

\$50-\$99

주향 김

Akif Turna
Ana Nunes
Angus Pratt
Annette McWilliams
Anonymous Donor
Aurora O'Brate
Barbara Bricalli
Bernard Carton
Bharathi Muthusamy
Biagio Ricciuti
Bruce Dunbar
Carlo Genova
Carolyn Presley
Carolyn Webster
Charles Simone
Christopher Garris
Clarissa Baldotto
Clarissa Mathias
Cui Zhang
Daniel Sammartino

David Fenwick
Deog Gon Cho
Doug Arenberg
Dwight Owen
Emily Stone
Estelamari Rodriguez
Etsuo Fujita
Evelyn CarrickFariborz (Fred)
Mortazavi
Fiona Hegi-Johnson
Francisco Orlandi Jorquera
Gabor Kari
Gilberto Castro Junior
Giovanni Selvaggi
Hanin Hussain
Heidi Mulqueen
Hirotsugu Kenmotsu
Hisako Harada
Hossein Borghaei
Hua Cheng
Jason Porter

Jeff Gahan
Jianjun Zhang
Jordi Remon
Judy Johnson
Ken Harrell
Kenneth O'Byrne
Leah Hamill
Marcia Horn
Maria Werner-Wasik
Maria Andrade Palacio
Mariam Grace Delima
Marie-Liesse Asselin-Labat
Mary Duffy
Melanie Janning
Miguel Munoz
Morten Quist
Naseer Ahmed
Navin S. Kanagasingam
Osarenren Ogbeide
Paul Wheatley-Price
Paula and Anne Mauro

Peter Briggs
Peter Illei
Philippe Joubert
Rayjean Hung
Rich Sullivan
Scott Murchie
Sonali Harchandani
Steve Kelsey
Susan Anderson
Thomas Ferber
Todd Sanft
Toshiyuki Harada
Wade Iams
Wenzhao Zhong
William Walsh
Yidan Qin
Yolande Lievens
Yoodhvir Nagar
Yuki Matsumura
Zulfiquer Otty
주향 김

Up To \$49

Alexander Kallimanis
Abbey Wrigley
Adiwirawan Mardjuadi
Aileen Murgatroyd
Alecsandra Anca Tudor
Alessandro Mariani
Alexandra Schuler
Amgad Moussa
Amy Grove
Ana Gelatti
Andres Felipe Cardona
Zorrilla
Annelies Goegebuer
Anonymous Donor
Anonymous Donor
Bo Lu
Bubse Na
Cengiz Gebitekin
Cesar Machado
Chao Zhang
Charu Kanwal
Chi Du
Christina Fernandez
Christopher Bulow
Cilla Trenado
Clare Bajraszewski
Dammi Seneviratne

Daniel Frausto
Daniel Shiri
Darsha Keehn
Dawei Yang
Kelsey Hecker
Ken Uchibori
Kengo Yasuda
Kevin Chua
Ki Hyeong Lee
Leslie LaChance
Loretta Schlegel
Lorraine Tyler
Lucia Viola
Lynn Sametz
Marco Matos
Margarita Garcia Fontes
Mariana Petaccia de Macedo
Mariana Laloni
Marija Jankova
Masaoki Ito
Masashi Yanada
Masaya Yotsukura
Matthew Hatton
Maureen Curran Pastore
Meng Welliver
MG Biopharma Consulting,
LLC

Miryana Pérez Vela
Murry Wynes
Mya Sadler
Natalia Valdiviezo
Neil Wallace
Nguyen Son Lam
Nisha Mohindra
Nobuyuki Yamamoto
Oleg Kshivets
Olga Tuulik
Patrick Arensdorf
Peggy Dennis
Rex Michael Santiago
Rob Pal
Robert Rintoul
Roselle de Guzman
Sally Paredes
Sampurna Chatterjee
Saravana Rajamanickam
Satoshi Shiono
Shan Chen
Shan He
Shinji Kaneda
Shota Nakamura
Shun-ichi Watanabe
Simon Ekman
Simon Ortino

Stella Isabel Martínez
Jaramillo
Stephan Soder
Sukhinder Atkar-Khattra
Sureyya Sarihan
Susan Weber
Suyog Jain
Sylvia Guetz
Tony Cheung
Toshihiko Kaneda
Tu Dao
Ulrike Gruber-
Moesenbacher
Victoria Lai
Wei Wang
William Mullally
Yanlin Zhang
Yeon Wook Kim
Yim Wah Lynn Shong
Yoshifumi Sano
Yoshiro Nakahara
Youjun Deng
Young Kwang Chae
Yu Mori
Yuhchayou Chen
Yvonne Diaz

[Click Here](#) For a Full List of Donors.

The Board of Directors 2023 -2025

BOARD OFFICERS



Paul Van Schil
President, Belgium



Karen Kelly
CEO, USA



Caicun Zhou
President-Elect, China



Heather Wakelee
Past-President, USA



Ming-Sound Tsao
Secretary, Canada



Joachim Aerts
Treasurer, Netherlands

Outgoing 2021-2023 Board of Director Members



Tetsuya Mitsudomi
Past-President, Japan



Andrea Bezjak
Secretary, Canada



Erik Thunnissen
Treasurer, Netherlands



Roy Herbst
Board Member, United States

BOARD MEMBERS



Joe Chang
USA



**Carlos Gil
Moreira Ferreira**
Brazil



Jhanelle Gray
USA



Young Tae Kim
South Korea



Natasha Leigh
Canada



Morten Quist
Denmark



Antoni Rosell
Spain



Lecia Sequist
USA



Benjamin Solomon
Australia



Paula Ugalde
USA



Ignacio Wistuba
USA



Wen-Zhao Zhong
China

IASLC STAFF

EXECUTIVE TEAM

Karen Kelly, MD

Chief Executive Officer

J. Michael Hoehn, CAE

Chief Operating Officer

Jennifer C. King, PhD

Chief Science Officer

John Skadow, CPA

Chief Financial Officer

Matt Yeingst, CFRE

Chief Development Officer

STAFF

Tessa Baxter

Development Program Manager

Becky Bunn

Director, Strategic Initiatives

Mya Burns

Associate Director, Conferences

Casey Connolly, MPH

Project Manager

Bailey Creamer

Editorial Assistant

Kathy Doherty

Director, Human Resources

Wanda Folsom

Education Manager

Rory Graham

Web Content Administrator

Ken Harrell

Associate Director,
Information Technology

Kelsey Hecker

Conference Coordinator

Kelly Heemsbergen

Conference Manager

O’Ryan Jackson

Development Specialist

Sara Lindsey Patton

Patient Advocacy Specialist

Katie Maher

Membership Specialist

Sunhee Malinowski

Controller

Jan Mazotti

Associate Director,
Communications & Marketing

Kahri Nestingen

Sponsorship & Exhibits
Coordinator

Kelly Nevins

Associate Director, Education

Rodrigo Sagastegui

Marketing Specialist

Savannah Spakes

Membership Coordinator

Kelsey Wood

Associate Director,
Membership

Laura Woodruff

Education Specialist

Murry Wynes, PhD

Senior Advisor, Scientific Affairs

Flavia Zarcula

Development Manager,
Corporate

The IASLC financial statements for the 2023 reporting period are currently being finalized and are not yet available for inclusion in this annual report. However, we assure you that our team is diligently working on completing and verifying these financials. Once the financial statements have undergone thorough review, audit, and approval processes, they will be promptly added to this report and made available to all stakeholders. We appreciate your patience and understanding in this matter and assure you of our commitment to providing accurate and transparent financial information.